Status:
COMPLETED
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
Lead Sponsor:
Galderma R&D
Conditions:
Psoriasis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.
Detailed Description
Same as above.
Eligibility Criteria
Inclusion
- Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved
Exclusion
- Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam
- Subjects whose psoriasis involves the scalp, face or groin
- Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00436540
Start Date
March 1 2006
End Date
January 1 2007
Last Update
July 29 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Solano Clinical Research
Vallejo, California, United States, 94589
2
Central Dermatology, PC
St Louis, Missouri, United States, 63117